Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
138.88
-3.70 (-2.60%)
Jun 27, 2025, 4:00 PM - Market closed
Krystal Biotech Employees
Krystal Biotech had 275 employees as of December 31, 2024. The number of employees increased by 46 or 20.09% compared to the previous year.
Employees
275
Change (1Y)
46
Growth (1Y)
20.09%
Revenue / Employee
$1,212,538
Profits / Employee
$450,764
Market Cap
4.01B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
KRYS News
- 4 days ago - Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa - GlobeNewsWire
- 7 weeks ago - Krystal Biotech to Present at BofA Securities 2025 Health Care Conference - GlobeNewsWire
- 7 weeks ago - Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - GlobeNewsWire
- 2 months ago - Krystal Biotech to Present at Upcoming Scientific Conferences - GlobeNewsWire
- 2 months ago - Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer - GlobeNewsWire
- 3 months ago - Krystal Biotech: Preparing To Chase Following Positive CHMP Opinion For VYJUVEK - Seeking Alpha
- 4 months ago - Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - GlobeNewsWire